JP5902704B2 - Ｈｉｖ複製の阻害剤 - Google Patents

Ｈｉｖ複製の阻害剤 Download PDF

Info

Publication number
JP5902704B2
JP5902704B2 JP2013538301A JP2013538301A JP5902704B2 JP 5902704 B2 JP5902704 B2 JP 5902704B2 JP 2013538301 A JP2013538301 A JP 2013538301A JP 2013538301 A JP2013538301 A JP 2013538301A JP 5902704 B2 JP5902704 B2 JP 5902704B2
Authority
JP
Japan
Prior art keywords
methyl
mmol
tetrahydro
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013538301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542247A (ja
JP2013542247A5 (https=
Inventor
サイモン ベル，アンドリュー
サイモン ベル，アンドリュー
ブライアン ガードナー，イアン
ブライアン ガードナー，イアン
キャメロン プライド，デビッド
キャメロン プライド，デビッド
ミシェル ウェイクンハット，フローリアン
ミシェル ウェイクンハット，フローリアン
リチャード ギブソン，カール
リチャード ギブソン，カール
Original Assignee
ヴィーブ ヘルスケア ユーケー リミテッド
ヴィーブ ヘルスケア ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィーブ ヘルスケア ユーケー リミテッド, ヴィーブ ヘルスケア ユーケー リミテッド filed Critical ヴィーブ ヘルスケア ユーケー リミテッド
Publication of JP2013542247A publication Critical patent/JP2013542247A/ja
Publication of JP2013542247A5 publication Critical patent/JP2013542247A5/ja
Application granted granted Critical
Publication of JP5902704B2 publication Critical patent/JP5902704B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013538301A 2010-11-15 2011-11-01 Ｈｉｖ複製の阻害剤 Expired - Fee Related JP5902704B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41361810P 2010-11-15 2010-11-15
US61/413,618 2010-11-15
US201161485355P 2011-05-12 2011-05-12
US61/485,355 2011-05-12
PCT/IB2011/054852 WO2012066442A1 (en) 2010-11-15 2011-11-01 Inhibitors of hiv replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016046384A Division JP2016164163A (ja) 2010-11-15 2016-03-10 Ｈｉｖ複製の阻害剤

Publications (3)

Publication Number Publication Date
JP2013542247A JP2013542247A (ja) 2013-11-21
JP2013542247A5 JP2013542247A5 (https=) 2014-12-18
JP5902704B2 true JP5902704B2 (ja) 2016-04-13

Family

ID=44999830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538301A Expired - Fee Related JP5902704B2 (ja) 2010-11-15 2011-11-01 Ｈｉｖ複製の阻害剤
JP2016046384A Pending JP2016164163A (ja) 2010-11-15 2016-03-10 Ｈｉｖ複製の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016046384A Pending JP2016164163A (ja) 2010-11-15 2016-03-10 Ｈｉｖ複製の阻害剤

Country Status (15)

Country Link
US (3) US8809363B2 (https=)
EP (1) EP2640729B1 (https=)
JP (2) JP5902704B2 (https=)
CN (2) CN103429595B (https=)
AR (1) AR083870A1 (https=)
AU (2) AU2011330850B2 (https=)
BR (1) BR112013011991A2 (https=)
CA (1) CA2817896A1 (https=)
CL (1) CL2013001338A1 (https=)
MX (1) MX343274B (https=)
RU (1) RU2564445C2 (https=)
TW (1) TWI445709B (https=)
UY (1) UY33729A (https=)
WO (1) WO2012066442A1 (https=)
ZA (1) ZA201303433B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016164163A (ja) * 2010-11-15 2016-09-08 ヴィーブ ヘルスケア ユーケー リミテッド Ｈｉｖ複製の阻害剤

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
WO2013062028A1 (ja) 2011-10-25 2013-05-02 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
WO2014164409A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
ES2619708T3 (es) 2013-03-13 2017-06-26 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de inmunodeficiencia humana
WO2014164467A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105008369B (zh) 2013-03-14 2017-07-11 百时美施贵宝公司 人类免疫缺陷病毒复制抑制剂
JP2016512558A (ja) 2013-03-14 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
AU2014302550A1 (en) 2013-06-25 2016-02-11 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
EP3105236B1 (en) 2014-02-12 2017-10-18 ViiV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9834566B2 (en) 2014-02-18 2017-12-05 VIIV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
PT3107913T (pt) 2014-02-19 2018-09-28 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
MX2017005060A (es) 2014-10-24 2017-07-05 Bristol Myers Squibb Co Compuestos atropisomeros triciclicos.
RS59707B1 (sr) 2014-10-24 2020-01-31 Bristol Myers Squibb Co Derivati karbazola
PE20190710A1 (es) 2014-10-24 2019-05-17 Bristol Myers Squibb Co Compuestos de indol carboxamida utiles como inhibidores de cinasas
EP3294277B1 (en) 2015-05-08 2021-01-20 Katholieke Universiteit Leuven Functional cure of retroviral infection
TWI700284B (zh) 2015-05-29 2020-08-01 日商塩野義製藥股份有限公司 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
CN111018912A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种抗病毒药物关键中间体的合成和纯化方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5489586A (en) * 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP1310488A4 (en) * 2000-08-09 2005-08-10 Mitsubishi Pharma Corp CONCENTRATED BICYCLIC AMID COMPOUNDS AND THEIR MEDICAL USE
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Ｈｉｖ阻害剤
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
CA2469592C (en) 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
MY138657A (en) 2001-12-21 2009-07-31 Tibotec Pharm Ltd broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
US7875604B2 (en) * 2004-02-04 2011-01-25 University Of Virginia Patent Foundation Compounds that inhibit HIV particle formation
JP2008524134A (ja) * 2004-12-17 2008-07-10 エフ．ホフマン−ラ ロシュ アーゲー Ｇａｂａ−ｂアロステリックエンハンサーとしてのチエノ−ピリジン誘導体
ES2402322T3 (es) * 2007-11-15 2013-04-30 Gilead Sciences, Inc. Inhibidores de la replicación del virus de la inmunodeficiencia humana
RU2402531C2 (ru) * 2008-09-24 2010-10-27 Александр Леонидович Гинцбург Биологически активные вещества, подавляющие патогенные бактерии
GB0908394D0 (en) * 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG181423A1 (en) 2009-12-23 2012-07-30 Univ Leuven Kath Novel antiviral compounds
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
EP2640729B1 (en) * 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibitors of hiv replication
WO2012102985A1 (en) 2011-01-24 2012-08-02 Glaxosmithkline Llc Isoquinoline compounds and methods for treating hiv
WO2013012649A1 (en) 2011-07-15 2013-01-24 Glaxosmithkline Llc Azaindole compounds and methods for treating hiv

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016164163A (ja) * 2010-11-15 2016-09-08 ヴィーブ ヘルスケア ユーケー リミテッド Ｈｉｖ複製の阻害剤

Also Published As

Publication number Publication date
JP2013542247A (ja) 2013-11-21
MX2013005486A (es) 2013-12-12
UY33729A (es) 2012-06-29
CL2013001338A1 (es) 2014-03-28
CN103429595A (zh) 2013-12-04
BR112013011991A2 (pt) 2016-08-30
US9447116B2 (en) 2016-09-20
US20140315927A1 (en) 2014-10-23
CN105330675A (zh) 2016-02-17
RU2564445C2 (ru) 2015-10-10
AU2011330850B2 (en) 2016-01-28
ZA201303433B (en) 2014-12-23
TWI445709B (zh) 2014-07-21
AU2011330850A1 (en) 2013-06-27
TW201300395A (zh) 2013-01-01
WO2012066442A1 (en) 2012-05-24
US20120136023A1 (en) 2012-05-31
EP2640729B1 (en) 2016-12-21
AR083870A1 (es) 2013-03-27
CN103429595B (zh) 2015-10-21
RU2013121788A (ru) 2014-12-27
JP2016164163A (ja) 2016-09-08
CA2817896A1 (en) 2012-05-24
US8809363B2 (en) 2014-08-19
EP2640729A1 (en) 2013-09-25
US20160355528A1 (en) 2016-12-08
MX343274B (es) 2016-10-31
AU2016202565A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
JP5902704B2 (ja) Ｈｉｖ複製の阻害剤
KR101483834B1 (ko) 항바이러스 화합물
JP5925394B2 (ja) 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体
US9096586B2 (en) Therapeutic compounds
JP5860197B1 (ja) ウイルス感染症を処置するための治療用化合物
US9540343B2 (en) Compounds for the treatment of HIV
JP5372751B2 (ja) Ａｚａ−ペプチドプロテアーゼ阻害剤
HK1173994A (en) Novel antiviral compounds
JP2006225388A (ja) ピペラジン誘導体

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160310

R150 Certificate of patent or registration of utility model

Ref document number: 5902704

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees